Phospho-SNCA (S129) Antibody

What is phosphorylated alpha-synuclein (pS129) and why is it important in neurodegenerative research?

Phosphorylated alpha-synuclein at serine 129 (pS129) has emerged as a critical marker of pathological alpha-synuclein in neurodegenerative disorders, particularly Parkinson's disease (PD) and related synucleinopathies. Alpha-synuclein is a neuronal protein that plays several roles in synaptic activity, including regulation of synaptic vesicle trafficking and subsequent neurotransmitter release . In its normal state, only a small fraction of alpha-synuclein is phosphorylated at S129, but this proportion increases dramatically to 90% in Lewy bodies and other pathological aggregates found in PD patients' brains . This post-translational modification is believed to be associated with the misfolding process that leads to protein aggregation and eventual neurodegeneration. Researchers target pS129 alpha-synuclein using specific antibodies to investigate, monitor, and quantify alpha-synuclein pathology in both brain tissue and peripheral samples from patients with neurodegenerative diseases .

How do pS129 antibodies function and what are their primary research applications?

Phospho-S129 antibodies are immunoglobulins specifically designed to recognize and bind to alpha-synuclein proteins that have been phosphorylated at the serine 129 residue. These antibodies function through epitope recognition, where the antibody's paratope selectively binds to the region containing the phosphorylated S129 site on the alpha-synuclein protein . In research applications, pS129 antibodies serve multiple critical functions including immunohistochemical detection of Lewy bodies and other alpha-synuclein aggregates in brain tissue sections, quantification of pathological alpha-synuclein in biological fluids using immunoassays, and monitoring disease progression through changes in pS129 alpha-synuclein levels . Additionally, these antibodies are employed in Western blotting to detect different molecular weight species of pS129 alpha-synuclein, including monomers, oligomers, and high-molecular-weight aggregates . The versatility of pS129 antibodies has made them indispensable tools for basic research into the pathophysiology of synucleinopathies, biomarker development, and therapeutic target identification.

What are the common limitations when using pS129 antibodies in experimental research?

Several significant limitations affect the reliability of pS129 antibody-based experiments in synucleinopathy research. Most critically, many pS129 antibodies exhibit cross-reactivity with other proteins, detecting non-specific low and high molecular weight bands in alpha-synuclein knock-out samples that can be easily misinterpreted as monomeric or high molecular weight alpha-synuclein species . Another major limitation is the variable detection of pS129 alpha-synuclein in the presence of neighboring post-translational modifications; modifications such as phosphorylation at tyrosine 125 or truncation at residue 133 or 135 can differentially influence pS129 detection by various antibodies . Additionally, pS129 alpha-synuclein detection in clinical samples is extremely sensitive to endogenous phosphatase activity, requiring immediate addition of phosphatase inhibitors during sample collection to prevent dephosphorylation and subsequent loss of signal . Matrix effects also impact detection, as evidenced by the inability to reliably detect pS129 alpha-synuclein in cerebrospinal fluid despite using ultrasensitive single-molecule counting technology immunoassays .

How should researchers evaluate and select appropriate pS129 antibodies for their specific experimental needs?

Researchers should implement a comprehensive evaluation strategy when selecting pS129 antibodies for their experiments. Begin by assessing antibody specificity using both positive controls (purified recombinant pS129 alpha-synuclein) and negative controls (non-phosphorylated alpha-synuclein and alpha-synuclein knockout samples) to ensure the antibody specifically recognizes the phosphorylated form . Evaluate the antibody's performance across multiple experimental platforms relevant to your research, including Western blotting, immunohistochemistry, or immunoassays, as antibody performance can vary significantly between applications . Consider the antibody's sensitivity to neighboring post-translational modifications, particularly if studying diverse alpha-synuclein species, as only two antibodies have been identified that remain insensitive to PTMs adjacent to the pS129 site . Assess the antibody's ability to detect both monomeric and aggregated forms of pS129 alpha-synuclein, as some antibodies may preferentially recognize specific conformational states . Finally, validate the antibody's performance in your specific experimental system using appropriate controls before conducting full-scale experiments to ensure reliable and reproducible results.

What validation controls are essential when using pS129 antibodies in neurodegeneration research?

Implementing a rigorous set of validation controls is crucial for ensuring reliable results when using pS129 antibodies. Alpha-synuclein knockout samples represent an essential negative control that should be routinely included to identify non-specific binding, as many pS129 antibodies detect bands in these samples that could be mistaken for alpha-synuclein species . Dephosphorylation controls using lambda phosphatase treatment of samples can confirm that the detected signal is phosphorylation-dependent and not due to cross-reactivity with non-phosphorylated epitopes . Recombinant protein standards comprising both phosphorylated and non-phosphorylated alpha-synuclein should be included to verify antibody specificity and establish detection limits . When examining clinical or biological samples, particularly plasma, phosphatase inhibitor-treated versus untreated sample comparisons are essential to evaluate the impact of endogenous phosphatases on signal detection . Additionally, sample matrix controls (such as spike-and-recovery experiments) should be conducted to assess potential matrix-dependent interference with antibody binding, which is particularly important when developing quantitative assays for clinical samples .

What are the optimal techniques for detecting pS129 alpha-synuclein in different biological samples?

Detection of pS129 alpha-synuclein requires tailored approaches for different biological matrices, each with specific optimization requirements. For brain tissue samples, immunohistochemistry with pS129 antibodies represents the gold standard, but researchers must include alpha-synuclein knockout controls to distinguish genuine signal from cross-reactivity, as many antibodies show non-specific binding in brain slices . When analyzing plasma samples, ultrasensitive single-molecule counting technology-based immunoassays provide the necessary sensitivity to detect low pg/ml concentrations, but samples must be collected with immediate addition of phosphatase inhibitors to prevent rapid dephosphorylation of pS129 alpha-synuclein . For cerebrospinal fluid analysis, standard detection methods have proven problematic due to matrix effects, and even ultrasensitive assays face recovery challenges despite the theoretical presence of pS129 alpha-synuclein . In cell culture models, Western blotting coupled with kinase co-expression (such as GRK1 or PLK2) enhances pS129 detection, while mutation controls (S129A) should be included to confirm signal specificity . For all sample types, sandwich immunoassay formats using a combination of capture and detection antibodies often provide superior specificity compared to single-antibody approaches, particularly when developing quantitative assays for clinical applications .

How can researchers accurately quantify pS129 alpha-synuclein levels in experimental and clinical samples?

Accurate quantification of pS129 alpha-synuclein requires careful consideration of multiple methodological factors to ensure reliable measurements. Researchers should employ ultrasensitive detection platforms such as single-molecule counting technology-based immunoassays, which can detect pS129 alpha-synuclein in the low pg/ml range, essential for clinical sample analysis . A dual-antibody approach is recommended, where one assay quantifies total alpha-synuclein and another specifically measures pS129 alpha-synuclein, using the same capture antibody in both assays to enable meaningful normalization of phosphorylated to total protein ratios . When working with plasma samples, immediate addition of phosphatase inhibitors at collection is critical, as pS129 alpha-synuclein is extremely sensitive to endogenous phosphatase activity that can rapidly decrease detectable levels . For all quantification methods, standard curves using recombinant pS129 alpha-synuclein are essential, and spike-recovery experiments should be performed to assess matrix effects that might interfere with detection . Additionally, researchers should report both absolute concentrations of pS129 alpha-synuclein and its proportion relative to total alpha-synuclein, as this ratio may provide more consistent results across different studies and better reflect the pathological state in neurodegenerative conditions .

What novel detection methods are being developed for pS129 alpha-synuclein research?

Cutting-edge detection methodologies are advancing the sensitivity and specificity of pS129 alpha-synuclein analysis in neurodegenerative research. Single-molecule counting technology-based immunoassays represent a significant breakthrough, enabling detection of pS129 alpha-synuclein in the low pg/ml range, which is critical for analyzing clinical samples with low analyte concentrations . This technology, which couples fluorescent sandwich immunoassays with single-molecule counting, has demonstrated superior sensitivity compared to traditional ELISA and Luminex approaches previously used for pS129 detection . Proximity ligation assays are being explored to detect specific conformations and aggregate forms of pS129 alpha-synuclein by requiring the close proximity of multiple epitopes for signal generation, potentially distinguishing pathological from physiological forms . Mass spectrometry-based approaches are increasingly employed to simultaneously detect multiple post-translational modifications on alpha-synuclein, allowing researchers to study the interplay between pS129 and other modifications without relying on antibody specificity . Additionally, advances in seed amplification assays, similar to RT-QuIC methodology used for prion detection, are being adapted to detect minute amounts of pathological pS129 alpha-synuclein seeds by their ability to induce aggregation of recombinant alpha-synuclein under controlled conditions .

What is the current evidence for using pS129 alpha-synuclein as a biomarker in neurodegenerative diseases?

The evidence supporting pS129 alpha-synuclein as a biomarker in neurodegenerative diseases shows promising but complex patterns across different biological matrices. In brain tissue, immunohistochemical detection of pS129 alpha-synuclein remains the definitive marker for Lewy bodies and Lewy neurites, with high specificity for synucleinopathies, making it a gold standard for neuropathological diagnosis . Plasma studies using ultrasensitive detection methods have demonstrated elevated levels of pS129 alpha-synuclein in Parkinson's disease patients compared to age-matched controls, suggesting potential utility as a peripheral disease marker . Researchers found that in a small cohort of 5 PD individuals and 5 age-matched controls, plasma pS129 alpha-synuclein levels were consistently higher in PD cases, indicating promise as a candidate diagnostic biomarker . In contrast, cerebrospinal fluid (CSF) has yielded contradictory results, with some studies reporting detectable pS129 alpha-synuclein levels around 60-220 pg/ml (approximately 12-15% of total alpha-synuclein), while others using ultrasensitive methods failed to detect it reliably, possibly due to matrix effects or rapid dephosphorylation . The longitudinal correlation between pS129 alpha-synuclein levels and disease progression appears non-linear according to recent studies, adding complexity to its use as a progression marker .

How do different kinases and phosphatases regulate alpha-synuclein phosphorylation at S129 in normal and pathological conditions?

The regulation of alpha-synuclein phosphorylation at S129 involves a complex interplay between various kinases and phosphatases that differs between normal physiology and pathological states. Several kinases have been identified that can phosphorylate alpha-synuclein at S129, including members of the G protein-coupled receptor kinase family (particularly GRK1), polo-like kinases (especially PLK2), and casein kinases (CK1 and CK2), with experimental evidence confirming their efficacy in cellular models . These kinases show differential activity patterns in normal versus pathological conditions, with some evidence suggesting upregulation of certain kinases in response to alpha-synuclein aggregation or cellular stress . Phosphatases responsible for dephosphorylating pS129 alpha-synuclein include protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1), which actively regulate the steady-state levels of pS129 alpha-synuclein . The extreme sensitivity of pS129 alpha-synuclein detection to phosphatase activity in clinical samples, particularly plasma, underscores the powerful regulatory role these enzymes play in controlling phosphorylation levels . In pathological conditions, evidence suggests a potential imbalance between kinase and phosphatase activities, possibly due to sequestration of alpha-synuclein in aggregates that may be less accessible to phosphatases, or to changes in enzyme expression or activity as part of the neurodegenerative process .

What are the common challenges in detecting pS129 alpha-synuclein in cerebrospinal fluid (CSF)?

Detection of pS129 alpha-synuclein in cerebrospinal fluid presents multiple technical challenges that have led to conflicting reports in the scientific literature. The most significant obstacle appears to be related to matrix effects, where components in the CSF interfere with antibody binding or signal generation, as evidenced by spike recovery experiments showing that pS129 alpha-synuclein was only partially recoverable in CSF despite being fully recoverable in other matrices . This matrix interference persisted despite pre-treatment with various denaturing agents designed to disrupt potential interfering protein interactions . Another major challenge is the potentially low abundance of pS129 alpha-synuclein in CSF relative to total alpha-synuclein, requiring extremely sensitive detection methods that approach the technical limits of current immunoassay technologies . Some studies have reported detectable levels of pS129 alpha-synuclein in CSF (approximately 60-220 pg/ml), while others using ultrasensitive single-molecule counting technology failed to detect it reliably, suggesting methodological differences or sample handling variations may play a significant role . Additionally, rapid dephosphorylation by endogenous phosphatases potentially occurs in CSF, although experiments adding phosphatase inhibitors at collection did not improve detection, suggesting this may not be the primary factor limiting CSF detection .

How can researchers address non-specific binding and cross-reactivity issues with pS129 antibodies?

Addressing non-specific binding and cross-reactivity issues with pS129 antibodies requires implementation of multiple complementary strategies throughout the experimental workflow. Always include alpha-synuclein knockout samples as negative controls to identify non-specific bands, as research has shown that most pS129 antibodies detect non-specific low and high molecular weight bands in knockout samples that could be misinterpreted as alpha-synuclein species . Employ pre-adsorption controls by pre-incubating the antibody with excess recombinant pS129 alpha-synuclein prior to sample application, which should substantially reduce or eliminate specific binding while leaving non-specific interactions unchanged . Consider using multiple pS129 antibodies raised against different epitopes or from different host species and compare the patterns of detection, as genuine pS129 signal should be consistent across antibodies while non-specific binding will likely vary . For immunohistochemistry applications, include secondary-only controls to identify background staining from the detection system, and consider antigen retrieval optimization to enhance specific epitope availability while reducing non-specific binding . In immunoassay development, employ a sandwich approach with two different antibodies (one for capture, one for detection) to dramatically improve specificity compared to single-antibody methods, as cross-reactive proteins are unlikely to bind both antibodies .

What sample collection and handling procedures are critical for maintaining pS129 alpha-synuclein integrity in clinical samples?

Preserving pS129 alpha-synuclein integrity in clinical samples requires strict adherence to specific collection and handling procedures tailored to each biological matrix. For plasma samples, immediate addition of phosphatase inhibitors at the time of collection is absolutely critical, as research has demonstrated that pS129 alpha-synuclein detection is extremely sensitive to endogenous phosphatase activity that can rapidly dephosphorylate the protein . Samples should be processed promptly after collection, with centrifugation performed at controlled temperatures (typically 4°C) to separate plasma or serum while minimizing degradation or dephosphorylation . Flash freezing of samples in liquid nitrogen following processing and storage at -80°C is recommended to preserve phosphorylation status for long-term storage, with avoidance of repeated freeze-thaw cycles that can lead to degradation of the phospho-epitope . During sample preparation for analysis, all buffers should contain fresh phosphatase inhibitor cocktails, and samples should be kept on ice whenever possible to minimize enzymatic activity . For tissue samples, rapid post-mortem processing is essential to preserve phosphorylation status, with immediate fixation in phosphatase inhibitor-containing fixatives if performing immunohistochemistry, or snap freezing if conducting biochemical analyses .

How might pS129 alpha-synuclein antibodies contribute to therapeutic development for synucleinopathies?

Phospho-S129 alpha-synuclein antibodies are enabling multiple therapeutic strategies that target the pathological forms of alpha-synuclein in synucleinopathies. Passive immunotherapy approaches using humanized pS129 alpha-synuclein antibodies are being explored as potential disease-modifying treatments, as these antibodies could selectively bind to pathological forms of alpha-synuclein and facilitate their clearance through microglial phagocytosis or autophagy pathways . The specificity of pS129 antibodies for the pathological form makes them particularly attractive for therapeutic targeting, potentially minimizing interference with normal alpha-synuclein function . Additionally, these antibodies are essential tools in preclinical evaluation of therapies targeting alpha-synuclein kinases or phosphatases, as they provide the means to measure treatment effects on phosphorylation levels in animal models and cell systems . In diagnostic applications, pS129 antibodies are enabling the development of imaging agents that could potentially detect alpha-synuclein pathology in living patients, which would represent a major breakthrough for early diagnosis and monitoring of treatment effects . Researchers are also exploring intrabodies (intracellularly expressed antibody fragments) derived from pS129 antibodies that could selectively target and neutralize pathological alpha-synuclein within neurons, offering a potential gene therapy approach .

What novel approaches are being developed to improve the specificity of pS129 alpha-synuclein detection?

Researchers are employing innovative strategies to enhance the specificity of pS129 alpha-synuclein detection for more accurate assessment of pathological processes. Conformation-specific antibodies that recognize particular three-dimensional structures of pS129 alpha-synuclein are being developed to distinguish between monomeric and various aggregated forms, potentially providing more pathologically relevant information than traditional antibodies that bind regardless of protein conformation . Bispecific antibody approaches that simultaneously target pS129 and another pathology-specific epitope on alpha-synuclein are being explored to increase specificity for particular pathological species, reducing the likelihood of detecting physiologically phosphorylated forms . Advanced immunoassay architectures incorporating multiple antibody recognition steps are being implemented, where signal generation requires sequential binding of multiple antibodies to different epitopes on the same protein molecule, dramatically reducing non-specific detection . Complementary non-antibody detection methods, such as mass spectrometry-based approaches, are being developed to verify antibody-based findings by providing orthogonal confirmation of phosphorylation status without reliance on epitope recognition . Additionally, researchers are exploring aptamer-based detection systems as alternatives to traditional antibodies, as these synthetic oligonucleotide sequences can be selected for extremely high specificity to particular protein conformations and may offer advantages in distinguishing between closely related phosphorylated species .

How is research on pS129 alpha-synuclein contributing to our understanding of disease progression and propagation in synucleinopathies?

Research using pS129 alpha-synuclein antibodies is revealing critical insights into the temporal and spatial dynamics of synucleinopathy progression. Immunohistochemical studies with pS129 antibodies have enabled detailed mapping of pathology progression through brain regions, supporting Braak's staging hypothesis that suggests alpha-synuclein pathology spreads in a predictable pattern from the brainstem to limbic regions and eventually to the neocortex . The ability to specifically detect pathological forms using pS129 antibodies has facilitated experiments tracking the cell-to-cell transmission of misfolded alpha-synuclein, revealing potential mechanisms of disease spread including direct synaptic transfer, exosome-mediated transport, and tunneling nanotube transmission . Studies examining the relationship between pS129 alpha-synuclein and other pathological protein modifications are elucidating the sequence of biochemical events in the aggregation process, with some evidence suggesting that phosphorylation may occur after initial misfolding but before mature fibril formation . Longitudinal analysis of pS129 alpha-synuclein in biological fluids is providing insights into biomarker dynamics throughout disease progression, with recent studies indicating a non-linear relationship between pS129 levels and disease state that challenges simplified models of pathology accumulation . Additionally, animal model studies using pS129 antibodies to track pathology are helping distinguish between regional vulnerability factors and connectivity-based spread, contributing to a more nuanced understanding of why certain neuronal populations are particularly susceptible to synucleinopathy .